研究单位：[1]Suzhou Koshine Biomedica, Inc.[2]Beijing Friendship Hospital, Capital Medical University,Beijing,China[3]Beijing Tongren Hospital, Capital Medical University,Beijing,China[4]China-Japan Friendship Hospital,Beijing,China[5]Peking University First Hospital,Beijing,China[6]Peking University People''s Hospital,Beijing,China[7]Xiangya Hospital Central South University,Changsha,China[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,China[9]Dermatology Hospital of Southern Medical University,Guangzhou,China[10]Sir Run Run Shaw Hospital of Zhejiang University School of Medicine,Hangzhou,China[11]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China[12]Huashan Hospital, Fudan University,Shanghai,China[13]Shenzhen People''s Hospital,Shenzhen,China[14]The First Hospital of Hebei Medical University,Shijiazhuang,China[15]Suining Central Hospital,Suining,China[16]The Second Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China
This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.
